Filing Flows › Metagenomi Therapeutics (MGX) › R&D spending
Metagenomi Therapeutics (MGX) R&D spending by quarter
Metagenomi Therapeutics' R&D spending was $19.3M in Q1 2026 (first quarter 2026), -10% from Q4 2025. Over the last 6 quarters it ranged from $19.3M (Q1 2026) to $25.3M (Q3 2025).
| Quarter | R&D spending | Q/Q | Y/Y |
|---|---|---|---|
| Q1 2026 | $19.3M | -10% | -23% |
| Q4 2025 | $21.5M | -15% | -7% |
| Q3 2025 | $25.3M | +12% | — |
| Q2 2025 | $22.5M | -10% | — |
| Q1 2025 | $25.1M | +9% | — |
| Q4 2024 | $23.2M | — | — |
Q1 2026 at a glance
Metagenomi Therapeutics, Q1 2026: revenue $1.2M (-70% year over year), net loss $23.1M, operating cash flow −$21.2M. The chart follows the revenue to costs, profit and cash.
Questions
What is Metagenomi Therapeutics' R&D spending?
Metagenomi Therapeutics' R&D spending was $19.3M in Q1 2026 (first quarter 2026), -10% from Q4 2025.
How has Metagenomi Therapeutics' R&D spending changed?
Over the last 6 quarters it ranged from $19.3M (Q1 2026) to $25.3M (Q3 2025).
Q1 2026 results → · How Metagenomi Therapeutics makes money →